Replies to post #199478 on Biotech Values

[DewDiligence]

AXON -28% on PFE’s discontinuing PF-05212377 in AD for lack of efficacy. AXON’s RVT-101 is from the same drug class.

[masterlongevity]

$pfe since Tafamidis trade name Vyndaqel) is not listed in their sales breakdkdowns, is it safe to assume they are selling <$50M per quarter.?